Monoclonal Antibodies has 4 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Efgartigimod Alfa, Efgartigimod Alfa And Hyaluronidase (Human Recombinant), Nipocalimab. Patients taking Monoclonal Antibodies should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 4
- Moderate
- 4
Moderate (4)
- Monoclonal Antibodies + Efgartigimod Alfa— Concomitant use may lower systemic exposures and reduce effectiveness of monoclonal antibodies. Closely monitor for redu…
- Monoclonal Antibodies + Efgartigimod Alfa And Hyaluronidase (Human Recombinant)— Concomitant use may lower systemic exposures and reduce effectiveness of monoclonal antibodies. Closely monitor for redu…
- Monoclonal Antibodies + Nipocalimab— Concomitant use may lower systemic exposures and reduce effectiveness of monoclonal antibodies. Closely monitor for redu…
- Monoclonal Antibodies + Rozanolixizumab— Concomitant use may lower systemic exposures and reduce effectiveness of monoclonal antibodies. Closely monitor for redu…